Between Medicines and Nutraceuticals in the Control of Diabetes Mellitus

Authors

  • Cheolin Park Department of Biomedical Laboratory Science, Daegu Health College, Daegu, KOREA
  • Youngdu Baek Department of Biomedical Laboratory Science, Daegu Health College, Daegu, KOREA

DOI:

https://doi.org/10.22270/ajprd.v12i2.1371

Abstract

Diabetes is a type of metabolic disease such as insufficient insulin secretion or poor functioning. It is characterized by high blood sugar, which increases blood glucose concentration, causes various symptoms and signs due to high blood sugar, and excrete glucose from urine.Diabetes mellitus is divided into types 1 and 2, and type 1 diabetes was previously called 'juvenile diabetes', and it is a disease caused by the inability to produce any insulin. Type 2 diabetes, which is relatively deficient in insulin, is characterized by insulin resistance.Insulin treatment is required for type 1 diabetes, but type 2 diabetes is based on lifestyle correction and may require additional drug administration. In addition, many patients or people concerned about diabetes use dietary supplements to control their blood sugar, but because of the side effects of prescription drugs and the lack of definitive clinical trials of dietary supplements, it is important to choose wisely between prescription drugs and dietary supplements with the advice of a physician or expert to treat or prevent diabetes.

 

Downloads

Download data is not yet available.

Author Biographies

Cheolin Park, Department of Biomedical Laboratory Science, Daegu Health College, Daegu, KOREA

Department of Biomedical Laboratory Science, Daegu Health College, Daegu, KOREA

Youngdu Baek, Department of Biomedical Laboratory Science, Daegu Health College, Daegu, KOREA

Department of Biomedical Laboratory Science, Daegu Health College, Daegu, KOREA

References

Cloete L. Diabetes mellitus: an overview of the types, symptoms, complications and management. Nurs Stand. 2022;Jan 5;37(1):61-66.

American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2011;Jan;34 Suppl 1(Suppl 1):S62-9.

Eizirik DL, Pasquali L, Cnop M.Pancreatic beta-cells in type 1 and type 2 diabetes mellitus: different pathways to failure.Nat Rev Endocrinol. 2020;Jul;16(7):349-362.

Salsali A, Nathan M.A review of types 1 and 2 diabetes mellitus and their treatment with insulin.Am J Ther. 2006;Jul-Aug;13(4):349-61.

Valla V.Therapeutics of diabetes mellitus: focus on insulin analogues and insulin pumps.Exp Diabetes Res. 2010;178372. doi: 10.1155/2010/178372. Epub 2010 May 26.

Semlitsch T, Engler J, Siebenhofer A, Jeitler K, Berghold A, Horvath K.(Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.Cochrane Database Syst Rev. 2020;Nov 9;11(11).

Thammakosol K, Sriphrapradang C. Effectiveness and safety of early insulin glargine administration in combination with continuous intravenous insulin infusion in the management of diabetic ketoacidosis: A randomized controlled trial. Diabetes ObesMetab. 2023; Mar;25(3):815-822.

Wu Y, Ding Y, Tanaka Y, Zhang W.Risk factors contributing to type 2 diabetes and recent advances in the treatment and prevention.Int J Med Sci. 2014;Sep 6;11(11):1185-200.

Seino S, Sugawara K, Yokoi N, Takahashi H. Beta-Cell signalling and insulin secretagogues: A path for improved diabetes therapy.Diabetes ObesMetab. 2017;Sep;19 Suppl 1:22-29.

Mitri J, Hamdy O. Diabetes medications and body weight.Expert Opin Drug Saf. 2009; Sep;8(5):573-84.

Herman R, Kravos NA, Jensterle M, Janež A, Dolžan V.Metformin and Insulin Resistance: A Review of the Underlying Mechanisms behind Changes in GLUT4-Mediated Glucose Transport.Int J Mol Sci. 2022;Jan 23;23(3):1264.

Drucker DJ.Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1.Cell Metab. 2018;Apr 3;27(4):740-756.

Aronson JK.Defining 'nutraceuticals': neither nutritious nor pharmaceutical.Br J Clin Pharmacol. 2017;Jan;83(1):8-19.

Jain N, Radhakrishnan A, Kuppusamy G.Review on nutraceuticals: phase transition from preventive to protective care.J Complement Integr Med. 2022;Apr 18;19(3):553-570

Hattori K, Sukenobu N, Sasaki T, Takasuga S, Hayashi T, Kasai R, Yamasaki K, Hazeki O. Activation of insulin receptors by lagerstroemin.J Pharmacol Sci.2003;93(1):69-73.

Miura T, Takagi S, Ishida T.Management of Diabetes and Its Complications with Banaba (Lagerstroemia speciosa L.) and Corosolic Acid.Evid Based Complement Alternat Med. 2012; 2012: 871495

Budrat P, Shotipruk A. Extraction of phenolic compounds from fruits of bitter melon (Momordica charantia) with subcritical water extraction and antioxidant activities of these extracts. Chiang Mai J Sci. 2008;35(1):123–130.

Sărăndan H, Botău D, Ianculov I, Radu F, Rada O, Morar D, et al.et al. The hypoglicemic effect of Momordica charantia Linn in normal and alloxan induced diabetic rabbits. Scientific Papers: Animal Science and Biotechnologies. 2010;43(1):516–518.

Cummings E, Hundal HS, Wackerhage H, Hope M, Belle M, Adeghate E, et al.et al. Momordica charantia fruit juice stimulates glucose and amino acid uptakes in L6 myotubes. Mol Cell Biochem. 2004;261:99–104.

Akhtar N, Khan BA, Majid A, Khan S, Mahmood T, Gulfishan, et al. Pharmaceutical and biopharmaceutical evaluation of extracts from different plant parts of indigenous origin for their hypoglycemic responses in rabbits. Acta Pol Pharm. 2011;68(6):919–925.

Uebanso T, Arai H, Taketani Y, Fukaya M, Yamamoto H, Mizuno A, et al.et al. Extracts of Momordica charantiasupress postprandial hyperglycemia in rats. J Nutr Sci Vitaminol (Tokyo) 2007;53(6):482–486.

Jeong J, Lee S, Hue J, Lee K, Nam SY, Yun YW, et al.et al. Effect of bittermelon (Momordica Charantia) on antidiabetic activity in C57BL/6J db/db mice. Korean J Vet Res. 2008;48(3):327–336

Abdollah M, Zuki ABZ, Goh YM, Rezaeizadeh A, Noordin MM. The effects of Momordica charantia on the liver in streptozotocin-induced diabetes in neonatal rats. Afr J Biotechnol. 2010;9(31):5004–5012.

Nerurkar PV, Lee YK, Nerurkar VR. Momordica charantia (bitter melon) inhibits primary human adipocyte differentiation by modulating adipogenic genes. BMC Complement Altern Med. 2010;10:34.

Alam MA, Uddin R, Subhan N, Rahman MM, Jain P, Reza HM.Beneficial role of bitter melon supplementation in obesity and related complications in metabolic syndrome.J Lipids. 2015;2015:496169. doi: 10.1155/2015/496169. Epub 2015 Jan 12.

Hamidpour, R.; Hamidpour, M.; Hamidpour, S.; Shahlari, M. Cinnamon from the selection of traditional applications to its novel effects on the inhibition of angiogenesis in cancer cells and prevention of Alzheimer’s disease, and a series of functions such as antioxidant, anticholesterol, antidiabetes, antibacterial, antifungal, nematicidal, acaracidal, and repellent activities. J. Tradit. Complement. Med. 2015;5:66–70.

Tran, H.N.H.; Graham, L.; Adukwu, E.C. In vitro antifungal activity of Cinnamomumzeylanicum bark and leaf essential oils against Candida albicans and Candida auris. Appl. Microbiol. Biotechnol. 2020;104:8911–8924.

Bento-Bernardes, T.; Toste, F.P.; Pazos-Moura, C.C.; Oliveira, K.J. Maternal cinnamon extract intake during lactation leads to sex-specific endocrine modifications in rat offspring. J. Sci. Food Agric. 2017;97:3855–3863.

Costello, R.B.; Dwyer, J.T.; Saldanha, L.; Bailey, R.L.; Merkel, J.; Wambogo, E. Do cinnamon supplements have a role in glycemic control in type 2 diabetes? A narrative review. J. Acad. Nutr. Diet 2016;116:1794–1802.

Hlebowicz, J.; Darwiche, G.; Bjorgell, O.; Almer, L.O. Effect of cinnamon on postprandial blood glucose, gastric emptying, and satiety in healthy subjects. Am. J. Clin. Nutr. 2007;85: 1552–1556.

Hayward, N.J.; McDougall, G.J.; Farag, S.; Allwood, J.W.; Austin, C.; Campbell, F.; Horgan, G.; Ranawana, V. Cinnamon shows antidiabetic properties that are species-specific: Effects on enzyme activity inhibition and starch digestion. Plant Foods Hum. Nutr. 2019;74:544–552.

Azam Borzoei, Maryam Rafraf, Shirin Niromanesh, LayaFarzadi, FatemeNarimani, and FaridehDoostan. Effects of cinnamon supplementation on antioxidant status and serum lipids in women with polycystic ovary syndrome. J Tradit Complement Med. 2018;Jan; 8(1): 128–133.

Syed Saqib Ali, Haseeb Ahsan, Mohammad Khalid Zia, Tooba Siddiqui, Fahim Halim Khan. Understanding oxidants and antioxidants: Classical team with new players. J Food Biochem. 2020; Mar;44(3)

Ilaria Liguori, Gennaro Russo, Francesco Curcio, Giulia Bulli, Luisa Aran, David Della-Morte, Gaetano Gargiulo, Gianluca Testa, Francesco Cacciatore, Domenico Bonaduce, and Pasquale Abete. Oxidative stress, aging, and diseases. Clin Interv Aging. 2018;13: 757–772.

Peter J Havel. A scientific review: the role of chromium in insulin resistance. Diabetes Educ. 2004;Suppl:2-14.

Anisha Prasad. Role of chromium compounds in diabetes. Indian Journal of Pharmacy and Pharmacology, January–March 2016;3(1):17-23

Zhao F, Pan D, Wang N, Xia H, Zhang H, Wang S, Sun G.Effect of Chromium Supplementation on Blood Glucose and Lipid Levels in Patients with Type 2 Diabetes Mellitus: a Systematic Review and Meta-analysis.Biol Trace Elem Res. 2022;200(2):516-525

Anderson RA. Chromium and diabetes. Nutrition. 1999;15(9):720-2.

Packer L, Cadenas E. Lipoic acid: energy metabolism and redox regulation of transcription and cell signaling. J Clin BiochemNutr. 2011;48(1):26-32.

Golbidi S, Badran M, Laher I. Diabetes and alpha lipoic Acid. Front Pharmacol. 2011;2:69.

Victoria Serhiyenko, Ludmila Serhiyenko, GalynaSuslik, AlexandrSerhiyenko. Alpha-lipoic acid: mechanisms of action and beneficial effects in the prevention and treatment of diabetic complications. Public Health. 2018;7(4):174-178.

Xu L, Zhang C, Bao J, Han G, Wang C, Cai Y, Xu G, Sun H, Liu M.Alpha-lipoic Acid Prevents Bone Loss in Type 2 Diabetes and Postmenopausal Osteoporosis Coexisting Conditions by Modulating the YAP/Glut4 Pathway.Cell BiochemBiophys. 2024;Jan 23. doi: 10.1007/s12013-024-01216-w.

Yifei Zhang 1, Xiaoying Li, Dajin Zou, Wei Liu, Jialin Yang, Na Zhu, Li Huo, Miao Wang, Jie Hong, Peihong Wu, Guoguang Ren, Guang Ning. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab. 2008; Jul;93(7):2559-65.

Hui Dong, Nan Wang, Li Zhao, and Fuer Lu. Berberine in the Treatment of Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis. Evidence-Based Complementary and Alternative Medicine. 2012;1-12.

Lan J, Zhao Y, Dong F, Yan Z, Zheng W, Fan J, Sun G. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension.J Ethnopharmacol. 2015;161:69-81.

Feng J, Wang X, Ye X, Ares I, Lopez-Torres B, Martínez M, Martínez-Larrañaga MR, Wang X, Anadón A, Martínez MA.Mitochondria as an important target of metformin: The mechanism of action, toxic and side effects, and new therapeutic applications.Pharmacol Res. 2022;177:106114. doi: 10.1016/j.phrs.2022.106114. Epub 2022 Feb 3.

Harsch IA, Kaestner RH, Konturek PC.Hypoglycemic side effects of sulfonylureas and repaglinide in ageing patients - knowledge and self-management.J PhysiolPharmacol. 2018; Aug;69(4). doi: 10.26402/jpp.2018.4.15. Epub 2018 Dec 9.

Kaur R, Kumar R, Dogra N, Kumar A, Yadav AK, Kumar M.Synthesis and studies of thiazolidinedione-isatin hybrids as alpha-glucosidase inhibitors for management of diabetes.Future Med Chem. 202;13(5):457-485.

Della-Morte D, Palmirotta R, Rehni AK, Pastore D, Capuani B, Pacifici F, De Marchis ML, Dave KR, Bellia A, Fogliame G, Ferroni P, Donadel G, Cacciatore F, Abete P, Dong C, Pileggi A, Roselli M, Ricordi C, Sbraccia P, Guadagni F, Rundek T, Lauro D.Pharmacogenomics and pharmacogenetics of thiazolidinediones: role in diabetes and cardiovascular risk factors.Pharmacogenomics. 2014;15(16):2063-82. doi: 10.2217/pgs.14.162.

Zinman B, Bhosekar V, Busch R, Holst I, Ludvik B, Thielke D, Thrasher J, Woo V, Philis-Tsimikas A.Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.Lancet Diabetes Endocrinol. 2019;7(5):356-367.

Molina-Vega M, Muñoz-Garach A, Fernández-García JC, Tinahones FJ.The safety of DPP-4 inhibitor and SGLT2 inhibitor combination therapies.Expert Opin Drug Saf. 2018;17(8):815-824.

Home P, Itzhak B.Is Insulin Therapy Safe?Am J Ther. 2020;Jan/Feb;27(1):e106-e114

Published

2024-04-15

How to Cite

Park, C., & Baek, Y. (2024). Between Medicines and Nutraceuticals in the Control of Diabetes Mellitus. Asian Journal of Pharmaceutical Research and Development, 12(2), 13–18. https://doi.org/10.22270/ajprd.v12i2.1371